Long-term safety of adalimumab in patients with moderate-to-severe ulcerative colitis: Interim results of a non-interventional registry, LEGACY

Bossuyt P, Atreya R, Taxonera C, Hebuterne X, Isaacs K, Higgins PD, Lindsay J, Heap G, Arikan D, Kuehnl V, Petersson J, Robinson AM, Loftus EV (2018)

Publication Type: Conference contribution

Publication year: 2018

Journal

Journal of Crohns & Colitis Elsevier

Book Volume: 12

Pages Range: S32-S32

DOI: 10.1093/ecco-jcc/jjx180.041

Authors with CRIS profile

Raja Atreya Professur für Translationale Immunforschung bei chronisch entzündlichen Darmerkrankungen (Heisenberg-Professur)

Involved external institutions

Imelda vzw BE Belgium (BE) University of Michigan US United States (USA) (US) University of Nice Sophia Antipolis / Université Nice Sophia Antipolis FR France (FR) AbbVie Deutschland GmbH & Co. KG DE Germany (DE) Hospital Clínico San Carlos ES Spain (ES) Queen Mary, University of London GB United Kingdom (GB) University of North Carolina at Chapel Hill US United States (USA) (US) Mayo Clinic US United States (USA) (US)

How to cite

APA:

Bossuyt, P., Atreya, R., Taxonera, C., Hebuterne, X., Isaacs, K., Higgins, P.D.,... Loftus, E.V. (2018). Long-term safety of adalimumab in patients with moderate-to-severe ulcerative colitis: Interim results of a non-interventional registry, LEGACY. (pp. S32-S32).

MLA:

Bossuyt, P., et al. "Long-term safety of adalimumab in patients with moderate-to-severe ulcerative colitis: Interim results of a non-interventional registry, LEGACY." 2018. S32-S32.

BibTeX: Download